AMPLEXOR in European Biopharmaceutical Review

by Romuald Braun, VP of Strategy at AMPLEXOR

With regulatory compliance growing, we should expect to see data management transformation rising. However, this is not the case.  Instead, we see companies throwing good money after bad money as they opt to invest in digitizing a process or updating an existing IT system. While, encouragingly, in 2019 organisations now appear to recognize the need for a more holistic approach, Life Sciences companies will need to focus attention on developing a vision for delivering this and mapping it to a hard strategy.  Read the full article and learn more about why it's important for Life Sciences companies to move from approaching each project in isolation, to viewing them as part of a bigger vision.

This article is taken from European Biopharmaceutical Review January 2019, pages 86-87. © Samedan Ltd.